Several radiopharmaceuticals, which target the presynaptic dopamine transporter (DAT) mediating the reuptake of dopamine from the synaptic cleft, derived from tropane and cocaine analogs, including [123I]N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane ([123I]fluoropropylcarbomethoxyiodophenylnortropane (FP-CIT), [123I]carbomethoxyiodo-phenyl-tropane ([123I]β-CIT), and [18F]FP-CIT have been used to assess the DAT location and density in the striatum, and their binding to DATs in the striatum is an important clue in the differential diagnosis of parkinsonism [7,8,9]. Here, SLC6A3 is linked to Parkinson disease.